Header Logo

Connection

PREMAL LULLA to Humans

Back to Details
This is a "connection" page, showing publications PREMAL LULLA has written about Humans.
PREMAL LULLA
Connection Strength
0.490
Humans
  1. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024 12 31; 20(1):2378543.
    View in: PubMed
    Score: 0.024
  2. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 03; 26(3):261-265.
    View in: PubMed
    Score: 0.023
  3. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
    View in: PubMed
    Score: 0.022
  4. Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27.
    View in: PubMed
    Score: 0.021
  5. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.020
  6. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2022 03 03; 139(9):1266-1267.
    View in: PubMed
    Score: 0.020
  7. COVID-specific T's may offset therapeutically endangered B's. Blood. 2022 01 06; 139(1):12-13.
    View in: PubMed
    Score: 0.020
  8. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
    View in: PubMed
    Score: 0.019
  9. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.019
  10. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Hum Vaccin Immunother. 2021 08 03; 17(8):2602-2616.
    View in: PubMed
    Score: 0.019
  11. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
    View in: PubMed
    Score: 0.018
  12. Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
    View in: PubMed
    Score: 0.017
  13. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207.
    View in: PubMed
    Score: 0.017
  14. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
    View in: PubMed
    Score: 0.016
  15. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540.
    View in: PubMed
    Score: 0.014
  16. Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9.
    View in: PubMed
    Score: 0.014
  17. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396.
    View in: PubMed
    Score: 0.014
  18. Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib. J Gastrointest Cancer. 2013 Mar; 44(1):98-101.
    View in: PubMed
    Score: 0.011
  19. Fatal paraneoplastic systemic leukocytoclastic vasculitis as a presenting feature of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S14-6.
    View in: PubMed
    Score: 0.010
  20. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
    View in: PubMed
    Score: 0.006
  21. Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Adv. 2025 Mar 11; 9(5):955-965.
    View in: PubMed
    Score: 0.006
  22. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
    View in: PubMed
    Score: 0.006
  23. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.006
  24. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
    View in: PubMed
    Score: 0.006
  25. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.006
  26. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
    View in: PubMed
    Score: 0.006
  27. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.006
  28. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024 03 28; 143(13):1269-1281.
    View in: PubMed
    Score: 0.006
  29. Bringing CAR T?cell therapy trials to underserved populations. Cancer Cell. 2023 12 11; 41(12):2007-2010.
    View in: PubMed
    Score: 0.006
  30. Banking on virus-specific T cells to fulfill the need for?off-the-shelf cell therapies. Blood. 2023 02 23; 141(8):877-885.
    View in: PubMed
    Score: 0.005
  31. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
    View in: PubMed
    Score: 0.005
  32. Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710.
    View in: PubMed
    Score: 0.005
  33. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
    View in: PubMed
    Score: 0.005
  34. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.005
  35. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.005
  36. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 01 25; 6(2):486-494.
    View in: PubMed
    Score: 0.005
  37. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
    View in: PubMed
    Score: 0.005
  38. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.005
  39. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
    View in: PubMed
    Score: 0.005
  40. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
    View in: PubMed
    Score: 0.004
  41. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020 01; 105(1):235-243.
    View in: PubMed
    Score: 0.004
  42. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
    View in: PubMed
    Score: 0.004
  43. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
    View in: PubMed
    Score: 0.004
  44. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
    View in: PubMed
    Score: 0.004
  45. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.004
  46. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
    View in: PubMed
    Score: 0.004
  47. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.004
  48. Retrospective review of extra-pulmonary small cell carcinoma and prognostic factors. Int J Clin Oncol. 2014 Oct; 19(5):822-8.
    View in: PubMed
    Score: 0.003
  49. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One. 2013; 8(10):e77409.
    View in: PubMed
    Score: 0.003
  50. Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate. Int J Clin Oncol. 2011 Dec; 16(6):722-5.
    View in: PubMed
    Score: 0.002
  51. The mandibular plane and mandibular rotation. Am J Orthod. 1976 Nov; 70(5):567-71.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.